Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1384&sort=funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1385&sort=funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1383&sort=funder" }, "data": [ { "type": "Grant", "id": "12146", "attributes": { "award_id": "1R01AG078268-01A1", "title": "Common Post-Infectious Premature Epigenetic Aging", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 21183, "first_name": "Max", "last_name": "Guo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-15", "end_date": "2028-04-30", "award_amount": 626306, "principal_investigator": { "id": 28006, "first_name": "Andrew R", "last_name": "DiNardo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 566, "ror": "https://ror.org/02pttbw34", "name": "Baylor College of Medicine", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: Last year in the United States, there were 1.3 million cases of pneumonia (excluding covid19). Worldwide, last year, there were 49 million cases respectively. Even after successful therapy, pneumonia and other severe infections are associated with >3-fold increased mortality risk due to increased cardiovascular disease, cancer, and recurrent infections. Preliminary evidence by our group and others have demonstrated that these severe infections induce detrimental premature epigenetic scars that accelerate age-associated epigenetic perturbations and induce pathologic inflammation and decrease immune responsiveness. While other studies have identified post-infectious premature aging, this study will be the first to identify which post-infectious premature aging epigenetic scars are associated with post-infectious mortality, inflammation and decreased immune responsiveness. We previously identified that post-infectious detrimental epigenetic scars last at least 6 months. Studies with longer-term follow up have confirmed these epigenetic scars are still present 82 weeks after resolution of the original insult. Therefore, we will follow participants with severe pneumonia for 24-months after completion of successful therapy and make use of cutting-edge single cell sequencing to clarify how these detrimental scars are persistently propagated. Our preliminary in vitro data demonstrates that infection induced premature epigenetic aging and immune perturbations can be mitigated by drugs that inhibit the TCA cycle such as metformin, everolimus, and metformin. This study will implement mechanistic studies to explore how inhibitors of the TCA can be used to alleviate post-infectious premature epigenetic scars and restore immune responsiveness.", "keywords": [ "Acceleration", "Age", "Aging", "Animal Model", "Animals", "Bacterial Pneumonia", "Benchmarking", "Bioinformatics", "COVID-19", "Cardiovascular Diseases", "Cell Aging", "Cells", "Cessation of life", "Cicatrix", "Citric Acid Cycle", "Clinical", "DNA", "DNA Methylation", "Data", "Enzymes", "Epigenetic Process", "Exclusion", "Genome", "Glean", "Human", "Hypermethylation", "Immune", "Immunity", "In Vitro", "Individual", "Infection", "Inflammation", "Malignant Neoplasms", "Metformin", "Modeling", "Outcome", "Participant", "Pathologic", "Patients", "Pharmaceutical Preparations", "Pneumonia", "Population", "Premature aging syndrome", "Recovery", "Resolution", "Risk", "SDZ RAD", "Sepsis", "Severity of illness", "Succinates", "Survivors", "T-Lymphocyte", "Testing", "Tricarboxylic Acids", "United States", "Viral Pneumonia", "Work", "alpha ketoglutarate", "clinically relevant", "cofactor", "epigenome", "epigenomics", "exhaust", "experimental study", "follow-up", "immune function", "improved", "in vivo", "inhibitor", "mortality", "mortality risk", "mouse model", "mycobacterial", "patient retention", "practical application", "premature", "preservation", "prevent", "progenitor", "recurrent infection", "single cell sequencing", "stem cells", "transcriptome sequencing" ], "approved": true } }, { "type": "Grant", "id": "12147", "attributes": { "award_id": "1UC7AI180308-01", "title": "Research Resources and Workforce Development for the Rocky Mountain Regional Biocontainment Laboratory at Colorado State University", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27982, "first_name": "FAYNA C", "last_name": "Diaz San Segundo", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-18", "end_date": "2028-07-31", "award_amount": 2751527, "principal_investigator": { "id": 24532, "first_name": "Karen Marie", "last_name": "Dobos", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 323, "ror": "https://ror.org/03k1gpj17", "name": "Colorado State University", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 323, "ror": "https://ror.org/03k1gpj17", "name": "Colorado State University", "address": "", "city": "", "state": "CO", "zip": "", "country": "United States", "approved": true }, "abstract": "Project Summary: The Rocky Mountain Regional Biocontainment Laboratory (RMRBL) at Colorado State University (CSU) has been responsive to the national RBL mission to: 1) “Conduct research on biodefense and emerging infectious disease agents”; 2) “Be available and prepared to assist national, state, and local public health efforts in the event of a bioterrorism or infectious disease emergency” since its opening and full commissioning in 2008. Researchers at the RMRBL and their collaborators rapidly pivoted in response to the emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), working on host-derived therapeutics, vaccines, and identifying other potential zoonotic reservoirs as spillover opportunities in wildlife and domestic animals. Our researchers similarly pivoted this past year to work on countermeasures in response to the re-emergence of Mpox, while also continuing to address high consequence pathogens that have chronically plagued public health systems, such as Mycobacterium tuberculosis, the causative agent of Tuberculosis. Beyond our demonstrated ability to rapidly address research and research service needs on pathogens with pandemic potential, our team contributes to training, outreach, and access of our facility via sponsored fellowships, visiting scholars’ programs, workshops, conferences, and through collaborations. Despite these gains, our RMRBL BSL3 suites are aged, requiring constant investments to maintain safe, secure and compliant BSL3 facilities. RMRBL BSL3 researchers, support staff, and biosafety professionals are vulnerable to the strain of the work environment, limited resources, funding gaps, and opportunities to engage in less risky fields equipped with cutting edge technologies. In this application, we respond to the challenges facing the RMRBL BSL3 laboratories with 3 Cores. Core 1 includes an improved management structure, systematic replacement of deprecating scientific instruments, and comprehensive and proactive maintenance of existing facilities needs to ensure compliance and continuous functioning. Operation of the RMRBL BSL3 is additionally enhanced to improve the working environment and increase consistency for operations research support and animal husbandry staff. Core 2’s initiatives seek to develop training programs responsive to adult learning and education best practices, ensuring improved safety and safety compliance in persons working in the BSL3. Biosecurity upgrades will improve the safety and security climate in anticipation of new national standards, and integration between research teams and the office of Biosafety in constructing and training in technical standard operating procedures will accelerate safe performance and technical competence. Finally, Core 3 synthesizes our research strengths to develop a uniquely qualified Biocontainment Research Resources Core, bringing together opportunities to exploit team talent and perform innovative research. Combined, our three Cores ensure that the RMRBL BSL3 facilities are always ‘warm ready’ – to face and combat the next pathogenic pandemic threat.", "keywords": [ "2019-nCoV", "Acceleration", "Address", "Adult", "American", "Animal Husbandry", "Biocompatible Materials", "Bioterrorism", "COVID-19", "Cells", "Chronic", "Climate", "Collaborations", "Colorado", "Communicable Diseases", "Communication", "Competence", "Dedications", "Development", "Diagnostic", "Disease", "Domestic Animals", "Education", "Educational process of instructing", "Educational workshop", "Emergency Situation", "Emerging Communicable Diseases", "Ensure", "Environment", "Equipment", "Event", "Evolution", "Face", "Fellowship", "Foundations", "Funding", "Goals", "Grant", "Health system", "In Vitro", "Infection", "Infectious Agent", "Information Technology", "Infrastructure", "Investments", "Laboratories", "Lead", "Learning", "Maintenance", "Mission", "Modeling", "Modernization", "Monkeypox", "Monoclonal Antibodies", "Mycobacterium tuberculosis", "National Institute of Allergy and Infectious Disease", "Operations Research", "Pathogenicity", "Performance", "Persons", "Procedures", "Public Health", "Qualifying", "Reagent", "Research", "Research Personnel", "Research Support", "Resource Development", "Resources", "Rodent", "Safety", "Scholars Program", "Secure", "Security", "Services", "Structure", "System", "Talents", "Technology", "Therapeutic", "Toxin", "Training", "Training Programs", "Training and Education", "Translating", "Tuberculosis", "Universities", "Vaccines", "Vision", "Work", "Workforce Development", "Zoonoses", "aged", "base", "biodefense", "biosafety level 3 facility", "biosecurity", "combat", "coronavirus disease", "design", "improved", "in vivo", "industry partner", "innovation", "instrument", "laboratory facility", "mass spectrometric imaging", "molecular mass", "operation", "outreach", "pandemic disease", "pandemic pathogen", "pandemic potential", "pathogen", "professional atmosphere", "programs", "recruit", "research facility", "response", "spillover event", "success", "symposium", "usability", "vaccine development", "visiting scholar" ], "approved": true } }, { "type": "Grant", "id": "12148", "attributes": { "award_id": "1R56AI174911-01A1", "title": "Investigating Multiple PK and PD Relationships for TB-HIV (IMPPRove TB-HIV)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 28007, "first_name": "Robert N.", "last_name": "Mahon III", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-21", "end_date": "2024-07-31", "award_amount": 817252, "principal_investigator": { "id": 28008, "first_name": "Kelly E.", "last_name": "Dooley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28009, "first_name": "Olivier", "last_name": "Marcy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28010, "first_name": "Vidya", "last_name": "Mave", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "Tuberculosis (TB) is the leading infectious cause of mortality globally after COVID-19. TB and HIV interact synergistically, each worsening the outcomes of the other. A key driver of unfavorable TB treatment outcomes is suboptimal drug exposures. However, target drug concentrations of first-line TB drugs and cumulative exposure thresholds needed for optimal clinical outcomes, post-TB lung health, and prevention of emergence of resistance are not defined, particularly in programmatic settings. In our study entitled “Investigating Multiple PK and PD Relationships for TB-HIV (IMPPRove TB-HIV),\" we will leverage the Tuberculosis Sentinel Research Network (TB SRN), a large global platform cohort study for coordinated observational TB research conducted among persons with pulmonary TB with and without HIV, within the International epidemiology Databases to Evaluate AIDS (IeDEA) consortium in six IeDEA regions, to conduct pharmacokinetic-pharmacodynamic (PK-PD) analyses, using a nested case-cohort design. We will measure individual PK via collection of dried blood spots (DBS), which are easy to collect, store, and ship, and cumulative drug exposure in hair, which reflects both adherence and PK. In Aim 1 (PK-PD aim), we will examine the impact of TB drug PK and cumulative drug exposure on risk of unfavorable TB treatment outcomes (death, failure, recurrence) among individuals with pulmonary TB, with or without HIV. In Aim 2 (PK-resistance aim), we will investigate the impact of drug exposures on emergence of TB drug resistance mutations. In Aim 3 (PK-lung health aim), we will evaluate the association between anti-TB drug exposures and post-TB lung disease and longitudinal lung health. Thus, the IMPPRove study aims to elucidate the relationships between drug exposures and unfavorable TB treatment outcomes, poor lung health, and resistance under field conditions, in a large multinational patient population, taking into account HIV status and other factors known to affect these outcomes. The goal is to inform optimization of TB treatment (right dose, right patient) to improve clinically-important outcomes for patients.", "keywords": [ "Acquired Immunodeficiency Syndrome", "Address", "Adherence", "Affect", "Antitubercular Agents", "Bacteria", "Biological", "Biological Response Modifier Therapy", "Blood", "COVID-19", "Cessation of life", "Clinical", "Cohort Studies", "Collaborations", "Collection", "Complement", "DNA", "Databases", "Disease", "Dose", "Drug Exposure", "Drug Interactions", "Drug Kinetics", "Drug Targeting", "Drug resistance", "Drug resistance in tuberculosis", "Dryness", "Enrollment", "Epidemiology", "Exposure to", "Failure", "Funding", "Genes", "Genetic Polymorphism", "Genotype", "Geography", "Goals", "HIV", "HIV/TB", "Hair", "Health", "Individual", "Inflammation", "Intermediate resistance", "International", "Knowledge", "Lung", "Lung diseases", "Measures", "Mediating", "Minority Groups", "Modeling", "Mutation", "Mycobacterium tuberculosis", "Outcome", "Participant", "Patient-Focused Outcomes", "Patients", "Persons", "Pharmaceutical Preparations", "Pharmacodynamics", "Play", "Prevention", "Pulmonary Tuberculosis", "Pyrazinamide", "Recurrence", "Relapse", "Research", "Research Design", "Research Personnel", "Resistance", "Rifampin", "Risk", "Role", "Sampling", "Science Enrichment", "Sentinel", "Site", "Spottings", "Sputum", "Toxic effect", "Treatment Failure", "Treatment outcome", "Tuberculosis", "United States National Institutes of Health", "Viremia", "Work", "acquired drug resistance", "care outcomes", "co-infection", "cohort", "design", "experience", "follow-up", "genome sequencing", "high risk", "improved", "isoniazid", "lung health", "lung injury", "mortality", "patient population", "pharmacokinetics and pharmacodynamics", "pharmacometrics", "pill", "prospective", "resistance mutation", "respiratory", "respiratory health", "sociodemographic factors", "sociodemographics", "therapeutic target", "treatment response", "tuberculosis drugs", "tuberculosis treatment", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "12149", "attributes": { "award_id": "1P01AI172531-01", "title": "Antibody Core", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-08-21", "end_date": "2028-05-31", "award_amount": 208535, "principal_investigator": { "id": 28011, "first_name": "Ali Hassan", "last_name": "Ellebedy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "The SARS-CoV-2 pandemic represents an exceptional public health crisis highlighting the need for better understanding of the mechanisms controlling broadly protective immune responses and generating vaccine candidates able to elicit such responses. The program project entitled “Programming Long-lasting Immunity to Coronaviruses (PLUTO)” proposes a comprehensive research plan towards designing pan-sarbecovirus and pan-betacoronavirus vaccines with broad protection by applying in-depth B cell characterization in the context of coronavirus immune histories imprinted by successive vaccinations and/or infections. Two complementary research projects will establish correlates of robust, durable and protective coronavirus humoral immunity (Project 1) as well as design and test efficacy of viral variant-proof pan-sarbecovirus and pan-betacoronavirus vaccines (Project 2). The Cores will synergize with the two research projects to support the successful completion of the research aims. The Administrative Core will manage the consortium, coordinate cross-project activities, and create the structure and environment needed to accomplish PLUTO’s goals. The Antibody Core will develop large panels of recombinant monoclonal antibodies (mAbs) against coronavirus spike proteins to define specificity and breath of immune responses elicited by coronavirus infections and/or vaccinations in humans and animal models. The Animal Model Core will provide a central resource with approvals, facilities, and expertise to assess efficacy of broadly cross-reactive coronavirus antibodies and vaccines in robust pre-clinical models against a spectrum of coronaviruses, including Select Agents. A multidisciplinary team of scientists from five institutions who have an outstanding track record of working collaboratively will conduct the proposed studies. The Research Projects will collaborate with each other and with the Antibody and Animal Model Cores, coordinated by the Administrative Core. The integrated and synergistic activities across Projects and Cores will drive the successful completion of the program project’s ambitious research agenda, enabling achievement of the long-term PLUTO goal of developing variant-proof pan-sarbecovirus and pan-betacoronavirus vaccines. These findings will contribute to curbing the current SARS-CoV-2 pandemic and mitigate the risk of future pandemics with coronaviruses.", "keywords": [ "2019-nCoV", "Acceleration", "Achievement", "Activities of Daily Living", "Animal Model", "Antibodies", "Antigens", "B-Lymphocytes", "Bacillus anthracis", "Binding", "Blood", "Bone Marrow", "COVID-19", "COVID-19 pandemic", "COVID-19 therapeutics", "Cell Separation", "Chronic", "Circulation", "Clinical", "Clinical Trials", "Clostridium difficile", "Collaborations", "Coronavirus", "Coronavirus Infections", "Coronavirus spike protein", "Development", "Diagnostic tests", "Dose", "Enterotoxins", "Environment", "Epitope Mapping", "Epitopes", "FDA approved", "Generations", "Goals", "Human", "Humoral Immunities", "Immune", "Immune response", "Immunity", "Immunize", "Immunologics", "Infection", "Inflammatory", "Institution", "Knowledge", "Life", "Malignant Neoplasms", "Maps", "Metabolic Diseases", "Methodology", "Middle East Respiratory Syndrome Coronavirus", "Moderna COVID-19 vaccine", "Monoclonal Antibodies", "Mus", "Neurons", "Nucleosides", "Peripheral Blood Mononuclear Cell", "Pfizer-BioNTech COVID-19 vaccine", "Pharmaceutical Preparations", "Pre-Clinical Model", "Productivity", "Proteins", "Public Health", "Publishing", "RNA vaccination", "RNA vaccine", "Recombinants", "Recording of previous events", "Research", "Research Project Grants", "Resources", "Respiratory syncytial virus", "SARS coronavirus", "SARS-CoV-2 antibody", "SARS-CoV-2 spike protein", "SARS-CoV-2 variant", "Sarbecovirus", "Scientist", "Screening procedure", "Specificity", "Specimen", "Structure", "Technology", "Therapeutic", "Time", "United States", "Universities", "Vaccination", "Vaccine Design", "Vaccinee", "Vaccines", "Variant", "Viral", "Virus", "Washington", "Work", "betacoronavirus", "betacoronavirus vaccine", "cohort", "coronavirus vaccination", "coronavirus vaccine", "cross reactivity", "design", "efficacy evaluation", "efficacy testing", "flexibility", "future pandemic", "human coronavirus", "human disease", "human model", "human monoclonal antibodies", "imprint", "improved", "insight", "lymph nodes", "multidisciplinary", "murine monoclonal antibody", "natural antibodies", "neutralizing antibody", "novel", "pathogenic microbe", "programs", "response", "risk mitigation", "single cell technology", "single-cell RNA sequencing", "synergism", "technology platform", "vaccine candidate", "vaccine development", "variants of concern", "ward" ], "approved": true } }, { "type": "Grant", "id": "12150", "attributes": { "award_id": "1F30DA057043-01", "title": "Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 12691, "first_name": "Yu", "last_name": "Lin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2027-07-31", "award_amount": 34508, "principal_investigator": { "id": 28012, "first_name": "Brianna", "last_name": "Evans", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1103, "ror": "", "name": "PENNSYLVANIA STATE UNIV HERSHEY MED CTR", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Opioid use disorder (OUD) is defined in the DSM-V as a “problematic pattern of opioid use leading to problems or distress”. More than 36,000 people overdosed on synthetic opioids including fentanyl in 2019 and, with the COVID-19 pandemic, there has been a 30% increase in overdose deaths.1,2 Current treatments for OUD include therapy and medication-assisted treatments (MATs) such as methadone, buprenorphine, and naltrexone. Naltrexone has low compliance rates and there is stigma associated with the use of methadone and buprenorphine, as they are opioids used to treat OUD. Access to these drugs, then, is limited, and relapse rates remain high.3-6,46 Relapse often is precipitated by withdrawal and withdrawal, we hypothesize, is a need state.7 Thus, as the need for fluid is sated by water, for example, the need for drug (i.e., withdrawal) is sated by drug. In accordance, we further hypothesized that glucagon-like peptide-1 (GLP-1), a satiety drug, could be utilized to reduce drug seeking and taking in rodent models of OUD. In support, GLP-1 targeted treatments are effective in reducing responding for many substances of abuse in rodent models.8,55-56,72 Additionally, we found that GLP-1 receptor agonists (GLP-1RAs) can reduce heroin self-administration, cue-induced heroin seeking, and drug-induced reinstatement of heroin seeking.9,24 GLP-1RAs also reduce oxycodone taking and seeking.15 Finally, our preliminary data suggest that a GLP-1RA can reduce cue- and drug-induced seeking of not only heroin, but fentanyl as well (Urbanik et al., in preparation). This finding is consistent with a recent report.13 With fentanyl contributing to the majority of opioid overdoses1, it is critical that we understand where in the brain fentanyl is acting and how treatment with a GLP-1RA might mitigate these effects. Here we will use rodent models, light sheet microscopy, qRT-PCR, and pharmacology to address these questions. For our rodent model, we will utilize an extended access drug self-administration paradigm.22 We predict that: (1) As with other drugs of abuse tested,16,22-23 half of the rats tested will be high drug takers and these rats will have higher cue-induced seeking and greater inhibition of the GLP-1 ‘satiety’ pathway and greater activation of reward substrates compared to low fentanyl taker/seekers. (2) Fentanyl intake, fentanyl seeking, brain activation patterns, and gene expression will be attenuated by treatment with the GLP-1RA, liraglutide. (3) The protective effects of GLP-1RA treatment on behavior and brain will be blocked by the administration of the GLP-1R antagonist, exendin-9 (Ex-9), directly into the lateral hypothalamus. These hypotheses will be tested across three specific aims. If our hypotheses are supported, we will have identified the most vulnerable of fentanyl taking and seeking rats, rescued these subjects from fentanyl seeking via treatment with a GLP-1RA, verified that fentanyl, particularly in the most vulnerable, inhibits the GLP-1 ‘satiety’ pathway and activates reward/seeking substrates, and implicated a key role for GLP-1 receptors in the lateral hypothalamus – a structure critically involved in homeostasis and motivated behavior.", "keywords": [ "Address", "Agonist", "Attenuated", "Behavior", "Behavioral", "Brain", "Buprenorphine", "COVID-19 pandemic", "Cues", "DSM-V", "Data", "Disease", "Distress", "Drug usage", "Economic Burden", "Exhibits", "Female", "Fentanyl", "GLP-I receptor", "Gene Expression", "Genes", "Healthcare", "Heroin", "Homeostasis", "Hypothalamic structure", "Individual Differences", "Infusion procedures", "Intake", "Lateral", "Light", "Liquid substance", "Mediating", "Methadone", "Microscopy", "Naltrexone", "Overdose", "Oxycodone", "Pathway interactions", "Pattern", "Persons", "Pharmaceutical Preparations", "Pharmacology", "Prediction of Response to Therapy", "Preparation", "Quantitative Reverse Transcriptase PCR", "Rattus", "Relapse", "Reporting", "Rewards", "Rodent Model", "Saline", "Satiation", "Self Administration", "Site", "Sprague-Dawley Rats", "Structure", "Substance Abuse Detection", "Substance of Abuse", "Testing", "United States", "Vulnerable Populations", "Water", "Withdrawal", "addiction", "antagonist", "care burden", "fentanyl seeking", "fentanyl use", "glucagon-like peptide 1", "innovation", "liraglutide", "male", "medication-assisted treatment", "motivated behavior", "neural circuit", "novel", "opioid overdose", "opioid use", "opioid use disorder", "overdose death", "protective effect", "social stigma", "synthetic opioid" ], "approved": true } }, { "type": "Grant", "id": "12151", "attributes": { "award_id": "1R01AG080635-01A1", "title": "Validation of the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for Diverse Populations", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 10682, "first_name": "DALLAS", "last_name": "ANDERSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-15", "end_date": "2028-05-31", "award_amount": 2101898, "principal_investigator": { "id": 28013, "first_name": "Ali", "last_name": "Ezzati", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28014, "first_name": "Richard B.", "last_name": "LIPTON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28015, "first_name": "Laura A.", "last_name": "Rabin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 741, "ror": "https://ror.org/05cf8a891", "name": "Albert Einstein College of Medicine", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "In-person administration is the current “gold-standard” for assessment of cognition and function in studies of Alzheimer’s disease and other dementia (ADRD). Remote neuropsychological assessment has been advocated to overcome various access barriers and decrease costs of neuropsychological services. Moreover, due to the pressing challenges and safety concerns imposed by the COVID-19 pandemic, there is an urgent need for robust methods for assessing and monitoring cognitive and functional status through remote assessments. The overall goal of the current project is to validate, refine, and calibrate the Remote Cognitive Aging and Alzheimer’s Disease REsearch (R-CARE) Toolbox for the assessment and monitoring of cognition and function in a diverse sample of initially dementia-free older adults. The toolbox will include measures from the Uniform Data Set, Neuropsychological Battery (UDSNB-3.0), complemented by frequently used tests in preclinical AD trials. In-person tests that pose challenges for remote administration will be replaced with tablet-based computerized tasks. We will recruit 600 dementia-free, racially/ethnically diverse (~ 1/3 non-Hispanic Black, 1/3 Hispanic, and 1/3 non- Hispanic White), community-residing participants aged ≥65 years. A randomized, counterbalanced design will be used to administer a comprehensive clinical and cognitive battery across both assessment modes (in-person vs. remote) separated by 2-6 weeks at baseline, with follow up visits at 18 and 36 months. Digital biomarkers (computerized tests and speech-based) and ADRD blood-based biomarkers will be collected. AIM 1: To evaluate the psychometric properties of remote cognitive tests and assess their validity against standard in-person tests. AIM 2: To evaluate comparability of longitudinal change in global cognition and within cognitive domains across modes of assessment (in-person vs remote) for the whole sample as well as subgroups defined by sex and race/ethnicity. AIM 3 (exploratory): To identify novel digital biomarkers that provide incremental validity for differentiating clinical and pathological disease stages, and for measuring and predicting cognitive and functional decline. Collectively, this study will validate remotely administered tests across different cognitive domains, provide evidence for cross-sectional and longitudinal validity, and provide normative data for remote tests in diverse populations. Our long-term goal is to develop an open-source, reliable and valid toolbox that would enable AD-researchers and clinicians to evaluate older adults from diverse backgrounds regardless of ability to attend in-person visits. 1", "keywords": [ "Acoustics", "Address", "Advocate", "Agreement", "Alzheimer&apos", "s Disease", "Alzheimer&apos", "s disease risk", "Amyloid beta-Protein", "Biological Markers", "Black race", "COVID-19 pandemic", "Calibration", "Caring", "Classification", "Clinical", "Clinical Trials", "Cognition", "Cognitive", "Cognitive aging", "Cohort Studies", "Communities", "Complement", "Data", "Data Collection", "Data Set", "Dementia", "Development", "Devices", "Digital biomarker", "Disease", "Disparity", "Elderly", "Electronic Health Record", "Ensure", "Ethnic Origin", "Ethnic Population", "Evaluation", "Frail Elderly", "Future", "Glial Fibrillary Acidic Protein", "Goals", "Grant", "Healthcare Systems", "Hispanic", "Impaired cognition", "Individual", "Intervention", "Measures", "Methods", "Modality", "Monitor", "Neuropsychological Tests", "Neuropsychology", "Not Hispanic or Latino", "Observational Study", "Participant", "Pathologic", "Pathology", "Patient Care", "Pattern", "Performance", "Persons", "Population Heterogeneity", "Property", "Psychometrics", "Race", "Randomized", "Research", "Research Personnel", "Risk", "Safety", "Sampling", "Semantics", "Services", "Speech", "Subgroup", "Tablets", "Telephone", "Testing", "Time", "Underserved Population", "Vaccination", "Validation", "Videoconferencing", "Visit", "blood-based biomarker", "clinical practice", "cognitive performance", "cognitive testing", "cohort", "computerized", "cost", "design", "digital", "ethnic diversity", "follow-up", "functional decline", "functional status", "human old age (65+)", "improved", "low socioeconomic status", "mild cognitive impairment", "neurofilament", "novel", "open source", "pandemic disease", "pre-clinical", "racial diversity", "racial population", "recruit", "remote administration", "remote assessment", "remote grading", "remote visit", "sex" ], "approved": true } }, { "type": "Grant", "id": "12152", "attributes": { "award_id": "1R41HL170874-01", "title": "Development of Antisense Oligonucleotides to Regulate Gamma' Fibrinogen Levels", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 24630, "first_name": "Ronald Q", "last_name": "Warren", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-24", "end_date": "2024-07-31", "award_amount": 277710, "principal_investigator": { "id": 28016, "first_name": "DAVID Henry", "last_name": "FARRELL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2068, "ror": "", "name": "GAMMA THERAPEUTICS, INC.", "address": "", "city": "", "state": "OR", "zip": "", "country": "United States", "approved": true }, "abstract": "g' (pronounced \"gamma prime\") fibrinogen (GPF) is an alternative splice isoform of the blood coagulation factor fibrinogen. This fibrinogen variant contains a high affinity binding site for the coagulation factor thrombin that localizes thrombin on the growing blood clot. Thrombin binds to GPF via thrombin's heparin binding site. This allows thrombin to continue forming the blood clot even in the presence of its inhibitor protein, antithrombin III, with the cofactor heparin. In addition, GPF forms clots that are resistant to breakdown by fibrinolytic enzymes, such that the clots persist in the blood vessel. Because of these activities, GPF is a risk factor for cardiovascular disease, including heart attacks and stroke. We have recently found that COVID-19 patients can develop extraordinarily high levels of GPF, which likely contributes to the thrombotic events that are seen in COVID-19 patients. In support of this hypothesis, critically ill COVID-19 patients are heparin resistant and do not benefit from heparin treatment. High GPF levels like these sequester thrombin in an active form that cannot be inhibited by antithrombin III/heparin. If the GPF levels could be lowered, many of these thrombotic events could likely be prevented. The Specific Aims of this application are therefore to: 1) Develop antisense morpholino oligos that bind their target g gene sequences and are taken up by the HepG2 human liver cell line. This will be accomplished using electrophoretic mobility shift assays to ensure that the antisense oligos bind to their target sequences. Cellular uptake into liver cells will be assayed using fluorescein-labeled oligos in a well- established tissue culture model of fibrinogen synthesis, the human HepG2 liver cell line. This cell line expresses both the gA and g' isoforms of the human g chain. 2) Optimize the morpholino oligomers for effectiveness in vivo using HepG2 cells. This will be accomplished by assaying the lead compounds developed in Aim 1 in HepG2 cells. The absolute levels and the relative expression ratios of the gA and g' mRNAs will be quantitated using RT-PCR. Total fibrinogen and GPF will be measured by ELISA. Milestones – The criteria for progress to animal studies in primates in Phase II are: 1. Development of antisense morpholino oligomers that bind their target g gene sequences. 2. Demonstration that the antisense morpholino oligomers modulate GPF levels in HepG2 liver cells.", "keywords": [ "Acute", "Affinity", "Age", "Alternative Splicing", "Animals", "Antisense Oligonucleotides", "Antisense Technology", "Antithrombin III", "Binding", "Binding Sites", "Biological Assay", "Blood", "Blood Coagulation Factor", "Blood Vessels", "Blood coagulation", "Body mass index", "C-reactive protein", "COVID-19", "COVID-19 patient", "COVID-19 severity", "Cardiovascular Diseases", "Cell Line", "Cells", "Chest Pain", "Clinic", "Coagulation Process", "Critical Illness", "Development", "Effectiveness", "Electrophoretic Mobility Shift Assay", "Enzyme-Linked Immunosorbent Assay", "Enzymes", "Event", "Exercise Tolerance", "F8 gene", "Fatigue", "Ferritin", "Fibrin", "Fibrin fragment D", "Fibrinogen", "Fluorescein", "Gender", "Genes", "Goals", "Hemophilia A", "HepG2", "Heparin", "Heparin Binding", "Hepatocyte", "Hospitalization", "Hospitals", "Human", "India", "Infection", "Interleukin-6", "Label", "Lactate Dehydrogenase", "Lead", "Long COVID", "Measures", "Messenger RNA", "Modeling", "Myocardial Infarction", "Normal Range", "Oligonucleotides", "Oxygen", "Patients", "Pharmaceutical Preparations", "Phase", "Primates", "Protein Isoforms", "Proteins", "ROC Curve", "Resistance", "Resolution", "Reverse Transcriptase Polymerase Chain Reaction", "SARS-CoV-2 infection", "Severity of illness", "Shortness of Breath", "Stroke", "Symptoms", "Syndrome", "Thrombin", "VWF gene", "Variant", "cardiovascular risk factor", "comorbidity", "coronavirus disease", "gamma Fibrinogen", "heparin cofactor", "in vivo", "indexing", "inhibitor", "medical schools", "post-COVID-19", "prevent", "severe COVID-19", "thrombotic", "tissue culture", "uptake" ], "approved": true } }, { "type": "Grant", "id": "12153", "attributes": { "award_id": "1R41HG013076-01A1", "title": "GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Human Genome Research Institute (NHGRI)" ], "program_reference_codes": [], "program_officials": [ { "id": 28017, "first_name": "RENEE ANNE", "last_name": "Rider", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-01", "end_date": "2024-07-31", "award_amount": 399948, "principal_investigator": { "id": 28018, "first_name": "Eric", "last_name": "Aaron", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 28019, "first_name": "RICHARD GABRIEL", "last_name": "FREEDMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 28020, "first_name": "ANDREA R", "last_name": "TILDEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2069, "ror": "", "name": "SMART INFORMATION FLOW TECHNOLOGIES", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "Genomics has become an essential element of biomedical science, playing multiple roles in rapidly addressing the COVID-19 pandemic, understanding medical complications to develop more effective preventative care and treatments, and modeling diseases in laboratory specimens for study. Despite the increasing relevance of genomics to people's everyday lives, genomics literacy in the United States remains low. In addition, the genomics workforce in the United States is still far from achieving the NHGRl's Strategic Vision with respect to diversity. To address these societal needs, it is critical to expose people to genomics careers and educate them on related topics while they contemplate future career pathways. To maximize the impact of such an effort, students at the high school and undergraduate level need access to a higher-quality genomics education to seed their interest in pursuing genomics careers and improve the diversity of the genomics workforce. To meet this critical need, SIFT, Colby College, and Jackson Labs propose GENOMICE (Game Exploring Nuances in Offspring to Master Interactions of Chromosome Expression), a low-cost, web-based digital game that teaches college and high school students to think about genomics quantitatively, probabilistically, and predictively through active engagement, strategic problem-solving, and customized feedback emulating how genomics instructors teach their students. Non-violent gameplay and characters representative of many dimensions of diversity will present an inclusive environment designed to appeal to students regardless of their experiences playing games. Phase I of this Small Business Technology Transfer (STTR) project will produce a low-fidelity prototype with tasks demonstrating specific game mechanics designed to teach core genomics concepts: identifying phenotypes, predicting genotypes, and developing breeding strategies to selectively produce offspring populations and traits (Aim 1 ). GENOMICE will also include a cutting-edge artificial intelligence (Al) system that monitors player performance and appropriately modifies game content to improve learning outcomes (Aim 2). GENOMICE's low-fidelity prototype will be evaluated in terms of usability and enjoyability in a pilot study with college students in introductory genomics courses (AIM 3). GENOMICE will be the first scalable, game-based, and adaptive genomics education tool targeting core genomics concepts and promoting transfer of in-game learning to traditional genomics assessments. GENOMICE will be a webbased game, allowing easy set up and scalability regardless of individual computers' capabilities. Making GENOMICE commercially available to universities, genomics research institutions, high schools, and the genomics industry has the potential to increase student engagement with genomics and give students of all backgrounds the skills needed for future genomics careers.", "keywords": [ "Achievement", "Address", "Albinism", "Alleles", "Artificial Intelligence", "Awareness", "Behavior", "Breeding", "Businesses", "COVID-19 pandemic", "Career Choice", "Chromosomes", "Cognitive", "Color", "Computer Models", "Computers", "Consult", "Decision Making", "Dimensions", "Disease model", "Education", "Educational Models", "Educational process of instructing", "Elements", "Ensure", "Environment", "Environment Design", "Expert Systems", "Exposure to", "Feedback", "Funding", "Future", "Genomics", "Genotype", "Goals", "Health", "Healthcare", "High School Student", "Individual", "Industry", "Institution", "Intervention", "Interview", "Judgment", "Laboratories", "Learning", "Measures", "Mechanics", "Minor", "Modeling", "Modernization", "Monitor", "Motivation", "Mus", "Mutation", "National Human Genome Research Institute", "Occupations", "Online Systems", "Parents", "Performance", "Persons", "Phase", "Phenotype", "Pilot Projects", "Play", "Population", "Preventive care", "Preventive treatment", "Problem Solving", "Quantitative Reasoning", "Recording of previous events", "Regulation", "Research", "Role", "Science", "Specimen", "Strategic vision", "Structure", "Students", "Technology", "Technology Transfer", "Testing", "Training", "Underrepresented Students", "United States", "Universities", "Work", "albino mouse", "analytical tool", "career", "college", "cost", "design", "digital", "empowerment", "experience", "health application", "high school", "improved", "instructor", "interest", "laboratory experience", "learning outcome", "literacy", "medical complication", "offspring", "pedagogy", "personalized learning", "pilot test", "programs", "prototype", "recruit", "skills", "student participation", "student training", "success", "tool", "trait", "undergraduate student", "university student", "usability" ], "approved": true } }, { "type": "Grant", "id": "12154", "attributes": { "award_id": "1R21AI176252-01", "title": "Dissecting the peptide motifs controlling coronavirus infections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27781, "first_name": "Mary Katherine Bradford", "last_name": "Plimack", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-10", "end_date": "2025-07-31", "award_amount": 222279, "principal_investigator": { "id": 28021, "first_name": "Thomas Miller", "last_name": "Gallagher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1513, "ror": "https://ror.org/04b6x2g63", "name": "Loyola University Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal aims to evaluate coronavirus assembly and egress. These late infection stages are understudied relative to coronavirus entry replication. Additional research is necessary to reveal how host cell machineries facilitate assembly and egress. Therefore, this proposal specifically focuses on coronavirus membrane proteins, their interactions with host cell components, and the relevance of these contacts to efficient virion formation and emergence from infected cells. Guided by biochemical and protein structural data documenting interfaces between viral peptide motifs and host coatomer and retromer complexes, we will construct recombinant murine coronaviruses and corona virus‐like particles with alternative motifs. Comparisons of recombinant virus infections, along with reductionist approaches assessing the formation and subcellular transport of virus‐like particles, will reveal how coatomer and retromer‐sorting nexins operate in controlling viral membrane protein trafficking, virus particle formation, and particle egress pathways. By expanding the studies to human pathogenic coronaviruses, we expect to identify commonly utilized host machineries that might be targeted by antiviral therapeutics.", "keywords": [ "Affect", "Antiviral Agents", "Binding", "Biochemical", "COVID-19 vaccine", "Cell membrane", "Cell surface", "Cells", "Cellular Structures", "Coat Protein Complex I", "Code", "Communication", "Complex", "Coronavirus", "Coronavirus Infections", "Cytoplasm", "Cytoplasmic Tail", "Data", "E protein", "Endoplasmic Reticulum", "Endosomes", "Foundations", "Goals", "Human", "Infection", "Integration Host Factors", "Knowledge", "Laboratories", "Membrane", "Membrane Proteins", "Methods", "Molecular Chaperones", "Mus", "Organelles", "Pathogenicity", "Pathway interactions", "Peptides", "Process", "Proteins", "Recombinants", "Recycling", "Research", "Site", "System", "Vesicle", "Viral", "Viral Matrix Proteins", "Viral Proteins", "Virion", "Virus", "Virus Diseases", "Virus-like particle", "comparative", "improved", "intracellular protein transport", "knockout gene", "novel coronavirus", "particle", "pharmacologic", "protein transport", "recombinant virus", "sorting nexins", "trafficking", "vesicle transport", "virus host interaction" ], "approved": true } }, { "type": "Grant", "id": "12155", "attributes": { "award_id": "1R01NR020940-01", "title": "Perceived Immigration Laws and Infectious Disease Control Measures", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 6234, "first_name": "Dionne", "last_name": "Godette", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-08-23", "end_date": "2028-05-31", "award_amount": 591201, "principal_investigator": { "id": 28022, "first_name": "CAROL L", "last_name": "GALLETLY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 700, "ror": "https://ror.org/00qqv6244", "name": "Medical College of Wisconsin", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "Over 44 million immigrants live in the US, and nearly half (44%) are Latinx. Historically, US immigrants have been reluctant to engage in public health infectious disease control measures such as testing, contact tracing, vaccination, and prompt medical care. Yet the public's cooperation is essential if infectious disease control measures are to succeed, especially among a marginalized subpopulation such as Latinx immigrants. Increasingly, commentators have noted the potential for immigration laws and concerns to deter immigrants from engaging in communicable disease control measures. This may be especially true for conditions of immigration significance that can be shrouded with negative legal and social connotations. Findings from our studies of Latinx immigrants' immigration concerns related to largely individual-level public health interventions--specifically use of services for HIV testing, substance use disorders and intimate partner violence--confirms commentators' concerns, (1R01MD011573 PI: Galletly) and our preliminary study of Latinx immigrants' legal concerns relevant to COVID testing, contact tracing, and treatment (R01MH091875-S1 PI: Galletly) strongly suggest this influence applies to large scale, population-level disease control efforts as well. The proposed study will extend our research on the influence of actual, and importantly, perceived, immigration-related laws on Latinx immigrants' use of HIV prevention services to examine the influence of these on Latinx immigrants' ability and willingness to engage in population-level disease control efforts where government direction is more prominent. Specifically, we propose to leverage the recent increased public awareness of public health disease control measures to examine the influence of actual and perceived immigration-related laws on Latinx immigrants' willingness to engage in testing, contact tracing, and treatment as recommended by public health representatives when indicated for tuberculosis, hepatitis C, and COVID-19. Our interdisciplinary team of researchers, attorneys, community health workers and public health representatives will collaborate on this mixed-methods, community-engaged study. Formative legal and qualitative inquiry to identify the nature, extent, and influence of immigration-related law concerns will inform the development of a de novo immigration law concerns measure to be administered to 1200 Latinx immigrants living in two US regions with diverse immigration environments. Participants with diverse documentation statuses, countries of origin, time spent in the US, and residence in rural/agricultural and urban settings will be purposively sampled to further inform analysis of these complex behaviors. Identifying actual and perceived legal barriers to immigrants' engagement in disease control measures can only be useful if results are transferred to practice. We will explore, with public health personnel, how best to support the rapid transfer of findings to practice. Given that US public health departments conduct, finance, or advise virtually all communicable disease control efforts, they are an ideal conduit for this.", "keywords": [ "AIDS prevention", "Address", "Agriculture", "Area", "Awareness", "Behavior", "COVID testing", "COVID-19", "COVID-19 pandemic", "Caring", "Charge", "Cities", "Collaborations", "Communicable Disease Control", "Communicable Diseases", "Communities", "Community Health Aides", "Community Health Nursing", "Complex", "Contact Tracing", "Country", "County", "Development", "Disease Management", "Documentation", "Environment", "Feedback", "Focus Groups", "Funding", "Gender", "Government", "HIV", "HIV Seropositivity", "Health", "Health Personnel", "Hepatitis B", "Hepatitis C", "Household", "Human immunodeficiency virus test", "Immigrant", "Immigration", "Individual", "Infection", "Intervention", "Interview", "Latinx", "Laws", "Lawyers", "Legal", "Measures", "Medical", "Methods", "Modeling", "Nature", "Occupational", "Participant", "Pattern", "Perception", "Policies", "Population", "Process", "Public Health", "Public Health Nursing", "Public Health Practice", "Recommendation", "Reporting", "Research", "Research Personnel", "Rural", "Sampling", "Scanning", "Sentinel", "Services", "Severities", "Structure", "Substance Use Disorder", "Surveys", "Testing", "Time", "Translating", "Tuberculosis", "Vaccination", "Work", "Writing", "behavior influence", "community organizations", "data exchange", "disorder control", "experience", "intimate partner violence", "marginalization", "member", "metropolitan", "pilot test", "prevention service", "public health intervention", "residence", "response", "screening", "social", "social stigma", "success", "transmission process", "urban setting", "virtual", "willingness" ], "approved": true } } ], "meta": { "pagination": { "page": 1384, "pages": 1392, "count": 13920 } } }